**
In a troubling revelation, internal records have surfaced showing that top officials from the Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, to discuss ongoing litigation related to the controversial glyphosate herbicide, Roundup. This meeting, held on June 17, 2025, occurred just months before the Trump administration took significant steps to bolster Bayer’s legal position in the Supreme Court, raising alarms about corporate influence on public health policy.
Close Encounters of Corporate and Government
The meeting at the EPA was attended by key figures including Lee Zeldin, the agency’s administrator, and Nancy Beck, who previously held a senior role at the American Chemistry Council before joining the EPA. During this encounter, discussions reportedly focused on “litigation” and “Supreme Court action,” specifically concerning Bayer’s strategies to counter a wave of lawsuits alleging that its glyphosate products have caused cancer among users.
Bayer has faced thousands of lawsuits claiming that the company failed to adequately warn consumers about the cancer risks associated with glyphosate, a chemical that has been a staple in agricultural practices for decades. Despite mounting evidence and numerous studies indicating potential health risks, Bayer’s approach has been to challenge the legal landscape, arguing that if the EPA does not mandate a cancer warning, they cannot be held liable.
Regulatory Support Amidst Controversy
In the aftermath of the June meeting, the Trump administration’s actions appeared to align closely with Bayer’s interests. A filing by D. John Sauer, the Trump-appointed solicitor general, urged the Supreme Court to hear Bayer’s case, a request that the court subsequently granted. Additionally, in February 2026, the White House invoked the Defense Production Act to ensure the continued production of glyphosate, effectively providing a level of government backing that many observers find alarming.
Nathan Donley, the environmental health science director for the Center for Biological Diversity, has voiced concerns over this relationship, stating, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” His remarks underline a growing sentiment that corporate interests are unduly influencing regulatory bodies.
The Public’s Right to be Heard
Legal experts and consumer safety advocates have raised red flags regarding the implications of such corporate meetings. Whitney Di Bona, an attorney at Drugwatch, questioned whether the EPA afforded similar opportunities for dialogue to individuals affected by glyphosate, noting the stark disparity in access to regulatory officials. “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup,” she stated, highlighting the need for a more equitable engagement process.
This sentiment resonates with advocacy groups like Moms Across America, whose founder, Zen Honeycutt, expressed no surprise at the revelations. “Coercion by chemical companies on our regulatory agencies is nothing new,” she remarked. Despite their efforts to engage with the EPA on pesticide safety, they have seen limited action taken on their concerns.
A Pattern of Corporate Influence
The meeting between Bayer’s executives and the EPA has drawn criticism for highlighting a potential pattern of privileged access enjoyed by corporate leaders. Naomi Oreskes, a professor at Harvard, pointed out that such access often contrasts sharply with the voices of ordinary citizens, who struggle to have their concerns heard. The implications of this dynamic extend beyond a single meeting; they suggest a systemic issue within the regulatory framework that prioritises corporate interests over public health.
Why it Matters
The revelations surrounding the EPA’s meeting with Bayer underscore a significant issue in the intersection of corporate power and public health policy. As the government appears to align itself with the interests of a powerful pesticide manufacturer, the health risks associated with glyphosate remain a pressing concern for many Americans. The ongoing litigation and the responses from those in power will determine not only the fate of Bayer but also the broader implications for environmental safety and consumer protection. The public deserves transparency and accountability in regulatory processes, especially when health is at stake. As advocates continue to challenge these dynamics, the need for reform in how corporate interests are managed within government agencies becomes increasingly urgent.
